secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001104659-23-089110
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q2 net loss $5.6M; merger with Morphimmune and $125M PIPE deal announced
--------------------------------------------------------------------------------

- Q2 net loss $5.6M ($0.46 per share) on $4.3M AbbVie collaboration revenue; R&D $5.7M, G&A $4.2M.
- Cash and cash equivalents $38.4M as of June 30, 2023.
- Definitive merger agreement with Morphimmune to combine platforms, expected close by end of 2023.
- Clay Siegall, ex-Seagen CEO, to serve as Chairman and CEO of combined company.
- Concurrent $125M private placement from institutional investors to support 3 IND filings within 18 months post-close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/0001104659-23-089110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923089110/tm2323035d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer